A, B., G, G., E, A., KS, C., S, U., A, B., . . . G, M. (2024). Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm. Blood advances, 8(11), 2695. https://doi.org/10.1182/bloodadvances.2024012565
Chicago Style (17th ed.) CitationA, Bataller, et al. "Therapy-related Chronic Myelomonocytic Leukemia Does Not Have the High-risk Features of a Therapy-related Neoplasm." Blood Advances 8, no. 11 (2024): 2695. https://doi.org/10.1182/bloodadvances.2024012565.
MLA (9th ed.) CitationA, Bataller, et al. "Therapy-related Chronic Myelomonocytic Leukemia Does Not Have the High-risk Features of a Therapy-related Neoplasm." Blood Advances, vol. 8, no. 11, 2024, p. 2695, https://doi.org/10.1182/bloodadvances.2024012565.
Warning: These citations may not always be 100% accurate.
